File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Biphasic emetic response of cyclophosphamide in the ferret

TitleBiphasic emetic response of cyclophosphamide in the ferret
Authors
Issue Date1997
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/pharmbiochembeh
Citation
Pharmacology Biochemistry And Behavior, 1997, v. 58 n. 1, p. 179-182 How to Cite?
AbstractCyclophosphamide (177 mg/kg, IV; n = 8) produced it biphasic emetic response in the ferret with a mean ± SE of 23.3 + 4.0 emetic episodes during a 4-h observation period. The emetic profile of cyclophosphamide showed a first phase with 18.6 ± 3.9 episodes and a second phase with 4.7 ± 1.2 episodes. Ondansetron (0.07 and 0.13 mg/kg, IV) and droperidol (0.25 and 0.79 mg/kg, IV) significantly reduced the number of emetic episodes in the first phase. Metoclopramide (2.24, 4.08, and 7.07 mg/kg, IV) also significantly reduced the number of emetic episodes in the first phase, and the dose of 7.07 mg/kg completely prevented emetic episodes in the second phase. In addition, ondansetron-treated ferrets (0.04, 0.07, and 0.13 mg/kg, IV) had a significant increase in the number of emetic episodes in the second phase.
Persistent Identifierhttp://hdl.handle.net/10722/188531
ISSN
2015 Impact Factor: 2.537
2015 SCImago Journal Rankings: 1.121
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, RHen_US
dc.contributor.authorLao, Len_US
dc.contributor.authorBerman, BMen_US
dc.contributor.authorCarter, AKen_US
dc.contributor.authorWynn, RLen_US
dc.date.accessioned2013-09-03T04:10:08Z-
dc.date.available2013-09-03T04:10:08Z-
dc.date.issued1997en_US
dc.identifier.citationPharmacology Biochemistry And Behavior, 1997, v. 58 n. 1, p. 179-182en_US
dc.identifier.issn0091-3057en_US
dc.identifier.urihttp://hdl.handle.net/10722/188531-
dc.description.abstractCyclophosphamide (177 mg/kg, IV; n = 8) produced it biphasic emetic response in the ferret with a mean ± SE of 23.3 + 4.0 emetic episodes during a 4-h observation period. The emetic profile of cyclophosphamide showed a first phase with 18.6 ± 3.9 episodes and a second phase with 4.7 ± 1.2 episodes. Ondansetron (0.07 and 0.13 mg/kg, IV) and droperidol (0.25 and 0.79 mg/kg, IV) significantly reduced the number of emetic episodes in the first phase. Metoclopramide (2.24, 4.08, and 7.07 mg/kg, IV) also significantly reduced the number of emetic episodes in the first phase, and the dose of 7.07 mg/kg completely prevented emetic episodes in the second phase. In addition, ondansetron-treated ferrets (0.04, 0.07, and 0.13 mg/kg, IV) had a significant increase in the number of emetic episodes in the second phase.en_US
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/pharmbiochembehen_US
dc.relation.ispartofPharmacology Biochemistry and Behavioren_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntiemetics - Pharmacologyen_US
dc.subject.meshAntineoplastic Agents, Alkylating - Administration & Dosage - Antagonists & Inhibitors - Pharmacologyen_US
dc.subject.meshCyclophosphamide - Administration & Dosage - Antagonists & Inhibitors - Pharmacologyen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDroperidol - Pharmacologyen_US
dc.subject.meshFerrets - Physiologyen_US
dc.subject.meshInjections, Intravenousen_US
dc.subject.meshMaleen_US
dc.subject.meshMetoclopramide - Pharmacologyen_US
dc.subject.meshOndansetron - Pharmacologyen_US
dc.subject.meshVomiting - Chemically Induceden_US
dc.titleBiphasic emetic response of cyclophosphamide in the ferreten_US
dc.typeArticleen_US
dc.identifier.emailLao, L: lxlao1@hku.hken_US
dc.identifier.authorityLao, L=rp01784en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0091-3057(97)00017-8en_US
dc.identifier.pmid9264088-
dc.identifier.scopuseid_2-s2.0-0030839424en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0030839424&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume58en_US
dc.identifier.issue1en_US
dc.identifier.spage179en_US
dc.identifier.epage182en_US
dc.identifier.isiWOS:A1997XP13500027-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridWong, RH=7402126848en_US
dc.identifier.scopusauthoridLao, L=7005681883en_US
dc.identifier.scopusauthoridBerman, BM=35458606800en_US
dc.identifier.scopusauthoridCarter, AK=16678419200en_US
dc.identifier.scopusauthoridWynn, RL=19537208500en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats